Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834130 | 1.00 | AKR1B1 (0.61) | AKR1B1MAOBMAOALMNAMAPT | |
| SCHEMBL4834698 | 0.82 | AKR1B1 (0.71) | AKR1B1MAOBMAOALMNAMAPT | |
| SCHEMBL4834701 | 0.82 | AKR1B1 (0.71) | AKR1B1MAOBMAOALMNAMAPT | |
| SCHEMBL17934346 | 0.78 | PIM1 (0.53) | MAOBMAOATDP1MEN1KMT2A | |
| SCHEMBL7464201 | 0.78 | CISD1 (0.71) | MAOBMAOALMNATDP1CISD1 | |
| SCHEMBL8388794 | 0.78 | CISD1 (0.71) | MAOBMAOALMNATDP1CISD1 | |
| SCHEMBL11321794 | 0.78 | CISD1 (0.71) | MAOBMAOALMNATDP1CISD1 | |
| SCHEMBL6692202 | 0.76 | PPARG (0.68) | AKR1B1MAOBMAOALMNAMAPT | |
| SCHEMBL6692200 | 0.76 | PPARG (0.68) | AKR1B1MAOBMAOALMNAMAPT | |
| SCHEMBL12177140 | 0.76 | CYP1A2 (0.53) | AKR1B1MAOBMAOAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | AKR1B1 393/4885MAOB 881/4885MAOA 1368/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | AKR1B1 393/4885MAOB 881/4885MAOA 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.